Slide 1: Top-Line Data Phase 2 CALDOSE-1 Trial in Ulcerative Colitis (UC)
Therape
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 216 of the Securities
Slide 3: Corporate Update
Slide 4: CALDOSE-1: Readout of Induction Phase Data
CALDOSE-1: Readout of Induction Phase Data Phase 2 Trial Design in Moderate-to-Severe UC, NCT03341962 Pe ' \ \ \ \ \ Placebo (n=64) > Placebo I Optional f ne (eine ————— Patients with open-label ' symptomatic ! extension ! remission H > 10mg IMU-838. QD period to q 30 mg IMU-838 QD atweeks | 7 oles
Slide 5: CALDOSE-1: Clinical Phase 2 Trial in UC
CALDOSE-1: Clinical Phase 2 Trial in UC NCT03341962 @ & QX\ Coordinating investigator: Dr. Geert D’Haens (AMC Amsterdam) Conducted with active IND in the United States Total number of patients randomized: 263 More than 100 sites in 19 countries: USA, Western, Central and Eastern Europe 209, Patient
Slide 6: CALDOSE-1: Demographics
CALDOSE-1: Demographics Stratification at Randomization for Prior Biologics and Concurrent Corticosteroid Use Treatment Groups 10mg 30mg 45 mg Total IMU-838 IMU-838 IMU-838 eal N % N % N % N % N % Concurrent Use of Corticosteroids No 28] 418| 26] 388] 26] 394| 26] 413| 106] 403 Yes Biologic-Naive Pa
Slide 7: CALDOSE-1: Clinical Remission
CALDOSE-1: Clinical Remission Primary Endpoint Not Achieved* 10mg 30mg 45mg peu eat IMU-838 | IMU-838 | IMU-833 DE Number of Randomized Patients | ©” £8 86 oh Number of Patients Meeting Primary 10 7 9 8 Endpoint \Clinical Remission Rate at Week 10 14.9% 10.6% 13.6% 12.5% The primary endpoint of clin
Slide 8: Interference Between Vidofludimus Calcium and Concurrent Use of Corticosteroids
Interference Between Vidofludimus Calcium and Concurrent Use of Corticosteroids Without Concurrent Steroids (n=125) 35.0% ange 29.5% 25.0% A 11.4% 20.0% Er 14.7% 15.0% 10.0% 5.0% 3.3% on | Clinical Symptomatic Remission Remission mPooled IMU-838 m™ Placebo 24.2% . Endoscopic Remission 35.0% 30.0% 25
Slide 9: Safety and Tolerability Profile of Vidofludimus Calcium in Line with Previous Investigations
Safety and Tolerability Profile of Vidofludimus Calcium in Line with Previous Investigations in Other Patient Populations The Safety and Tolerability Profile of Vidofludimus Calcium in the CALDOSE-1 Trial Was in Line with Previous Trials = Noincrease in infections or infestations as compared to plac
Slide 10: Summary of Clinical Trial Results
Summary of Clinical Trial Results Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in UC = Primary endpoint was not achieved as a result of an unexpected interference between vidofludimus calcium and concurrent use of corticosteroids: — Patient population without concurrent use of corticosteroids (ab
Slide 11: Corporate Update
Slide 12: Strategic Conclusions
Strategic Conclusions Multiple Advanced Clinical-Stage Programs with Upcoming Value Inflection Points Immunic will take this opportunity to sharpen its focus R&D personnel and financial resources can be focused on its other promising programs Vidofludimus Calcium Development Program in Neurology is
Slide 13: Multiple Clinical Data Readouts Expected Throughout 2022
Multiple Clinical Data Readouts Expected Throughout 2022 Program _| Target Preclinical Phase 1 Phase 2 Phase 3 Key Milestones RMS interim analysis planned after approx. half of the events occurred PMS interim analysis planned after half of the patients completed 24 weeks of treatment Vidofludimus Ca
Slide 14: EMPhASIS Trial: Strong Reduction of MRI Lesion Activity
EMPhASIS Trial: Strong Reduction of MRI Lesion Activity Pooled Cohorts 1 & 2 Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Phase 2 Trial in RRMS * Blinded main treatment period of 24 weeks = Randomized 268 patients in 36 centers across four European countries = Cohort 1: 30 and 45 mg
Slide 15: EMPhASIS Trial: Encouraging Signals of Neuroprotective Effects
EMPhASIS Trial: Encouraging Signals of Neuroprotective Effects Based on EDSS Assessments, Pooled Cohorts 1 & 2 Change of EDSS from Baseline to Week 24 Proportion of Patients With Unconfirmed EDSS Progression up to Week 24 Percent 21.1% : | i — ae 118% 1% 28 —_—_—_— a 25 5 24 4 Baseline Week 12 Week
Slide 16: EMPhASIS Trial: Relative Change of Serum NfL Concentrations
EMPhASIS Trial: Relative Change of Serum NfL Concentrations Versus Placebo After 24 Weeks, Pooled Cohorts 1 & 2 50% The relative change of serum neurofilament light chain versus placebo is proportional to vidofludimus calcium dose. = May reflect increasing trough -9% levels and related improved effe
Slide 17: Vidofludimus Calcium Showed Interesting Hints for Clinical Anti-Infection and Anti-SARS-CoV-2 Activity
Vidofludimus Calcium Showed Interesting Hints for Clinical Anti-Infection and Anti-SARS-CoV-2 Activity iy Treatment Corresponds with Decreased Number of Opportunistic COVID-19 Infections Treatment Does Not Interfere With Antibody Development During SARS-CoV-2 Infection 35% 33.0% 30% 25.0% zg 25% 2g
Slide 18: Multiple Clinical Data Readouts Expected Throughout 2022
Multiple Clinical Data Readouts Expected Throughout 2022 Program _| Target Preclinical Phase 1 Phase 2 Phase 3 Key Milestones RMS interim analysis planned after approx. half of the events occurred PMS interim analysis planned after half of the patients completed 24 weeks of treatment Vidofludimus Ca
Slide 19: IMU-935 Phase 1 Clinical Trial
IMU-935 Phase 1 Clinical Trial Trial Design and Current Status PART NA Evaluation of single ascending doses (SAD) Healthy human subjects randomized to receive single dose of IMU-935 or placebo Final PK analy enroll Pk: pharmacokinetic; QD: quaque die once-daily; BD: bisindie=two times daily 19 | ©im
Slide 20: IMU-935 Phase 1 Clinical Trial: Part C
IMU-935 Phase 1 Clinical Trial Part Cin Moderate-to-Severe Psoriasis Patients Detecting Therapeutic Activity of IMU-935 in Moderate-to-Severe Psoriasis Patients = Double-blind, placebo-controlled dose escalation study to evaluate safety, tolerability, pharmacodynamics and exploratory efficacy of IMU
Slide 21: Multiple Clinical Data Readouts Expected Throughout 2022
Multiple Clinical Data Readouts Expected Throughout 2022 Program _| Target Preclinical Phase 1 Phase 2 Phase 3 Key Milestones * RMS interim analysis planned after approx. half of the events occurred = PMSinterim analysis planned after half of the patients completed 24 weeks of treatment Vidofludimus
Slide 22: Celiac Disease is a Serious Autoimmune Disease
Celiac Disease is a Serious Autoimmune Disease Celiac disease is a multifactorial, complex autoimmune disease caused by an immune reaction against a degradation product of gluten and is strongly associated with specific HLA class Il gene variants (HLA-DQ2 and -DQg)!! * Gluten is degraded into gliadi
Slide 23: Celiac Disease Currently Has No Adequate Treatment Options
Celiac Disease Currently Has No Adequate Treatment Options How much is 10 mg of gluten? 10 mg of gluten is the total limit for all foods combined for the entire day. 23 | ©immunic, inc. | Jun/02/2022 The Only Option Today is a Gluten Free Diet!1] Symptomatic Patients Despite Gluten Free Diet = The o
Slide 24: Patients Across the Spectrum of Celiac Disease Need Access to a Drug Treatment
Patients Across the Spectrum of Celiac Disease Need Access to a Drug Treatment to Address Persistent Disease Activity Despite GFD Active Celiac Disease = Numerous, intense Gl symptoms = Marked by enterocyte atrophy * Antibody stimulation in (barrier fully compromised) response to gluten / gliadin =
Slide 25: IMU-856: Three-Part, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Trial
IMU-856: Three-Part, Double-Blind, Randomized, Placebo- Controlled Phase 1 Clinical Trial Perf datA . 10 Sites i er oe ee. _ Flow Chart of Part C in Celiac Disease Australia and New Zealand = Conducted in three parts: — Safety and pharmacokinetics in healthy human subjects (Part A: single ascending
Slide 26: Multiple Clinical Data Readouts Expected Throughout 2022
Multiple Clinical Data Readouts Expected Throughout 2022 ty & Advanced clinical pipeline: three differentiated investigational medicines in various phases of clinical development RMS phase 3 program of vidofludimus calcium ongoing, intended to provide a straightforward path towards regulatory approv
Slide 27: Q&A Session
Slide 28: Immunic currently has three investigational medicines in active clinical trials
i= Immunic WHERAPEUMILES Immunic currently has three investigational medicines in active clinical trials from phase 1 to phase 3 with multiple important data readouts ahead in H2/2022 = Discussions planned with clinical experts and potential partners to enhance the understanding of the strategic imp
Slide 29: Thank You!
Thank You! Head of IR & Communications Phone: +49-89-2080477-09 Email: ir@imux.com w.imux.com 29 | ©immunic, inc. | Jun/02/2022 Immunic, Inc. Immunic AG 1200 Avenue of the Americas Lochhamer Schlag 21 New York City, NY 10036 82166 Gréfelfing (Munich) USA Germany Immunic Research GmbH Weinberg Campus